Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 22:2021:2328402.
doi: 10.1155/2021/2328402. eCollection 2021.

Mucopolysaccharidosis Type II: A Kenyan Case Series

Affiliations

Mucopolysaccharidosis Type II: A Kenyan Case Series

L N Wainaina Mungai et al. Int J Endocrinol. .

Abstract

Hunter syndrome, or mucopolysaccharidosis type 2 (MPS2), is a lysosomal storage disorder associated with the involvement of multiple organs such as the central nervous system, hepatomegaly, musculoskeletal, respiratory, cardiac, and hearing. This is due to the accumulation of glycosaminoglycans in body tissues leading to organ failure. Since the laboratories in Kenya do not screen for metabolic diseases, there is the likelihood of assumption that these patients do not exist. These first cases were referred from the eastern part of Kenya where the majority of inhabitants are from the same ethnic community. It was noted that there was increased mortality among boys below the age of 20 years, and hence, the families sought for help in the national referral and teaching hospital. The case series is meant to show that these cases exist and the majority of the patients may be dying before the diagnosis is made. There are no data on MPS2 from Kenya, and the prevalence and incidence are unknown. In this retrospective study, we present a case series of 6 Kenyan boys with MPS2 from a national referral hospital. They were part of 17 patients who had had their blood analyzed for metabolic diseases. All of them were symptomatic with varying degrees of central nervous system involvement. They had undetectable levels of iduronate-2-sulfatase (I2S) enzyme, and three genetic mutations were detected in the IDS gene.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Martin R., Beck M., Eng C., et al. Recognition and diagnosis of mucopolysaccharidosis II (hunter syndrome) Pediatrics . 2008;121(2):e377–e386. doi: 10.1542/peds.2007-1350. - DOI - PubMed
    1. Neufeld E. F. The Metabolic and Molecular Bases of Inherited Disease . Berlin, Germany: Springer; 2001. The mucopolysaccharidoses; pp. 3421–3452.
    1. Chen Y. The Metabolic and Molecular Bases of Inherited Disease . New York, NY, USA: McGraw-Hill; 2001.
    1. Vafiadaki E., Cooper A., Heptinstall L. E., Hatton C. E., Thornley M., Wraith J. E. Mutation analysis in 57 unrelated patients with MPS II (hunter’s disease) Archives of Disease in Childhood . 1998;79(3):237–241. doi: 10.1136/adc.79.3.237. - DOI - PMC - PubMed
    1. Wraith J. E., Scarpa M., Beck M., et al. Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics . 2008;167(3):267–277. doi: 10.1007/s00431-007-0635-4. - DOI - PMC - PubMed

LinkOut - more resources